Results 171 to 180 of about 11,049 (220)
Some of the next articles are maybe not open access.
Continuum, 2022
Status epilepticus is a serious condition caused by disorders and diseases that affect the central nervous system. In status epilepticus, hypersynchronous epileptic activity lasts longer than the usual duration of isolated self-limited seizures (time t1), which causes neuronal damage or alteration of neuronal networks at a certain time point (time t2),
Eugen, Trinka, Markus, Leitinger
openaire +2 more sources
Status epilepticus is a serious condition caused by disorders and diseases that affect the central nervous system. In status epilepticus, hypersynchronous epileptic activity lasts longer than the usual duration of isolated self-limited seizures (time t1), which causes neuronal damage or alteration of neuronal networks at a certain time point (time t2),
Eugen, Trinka, Markus, Leitinger
openaire +2 more sources
Status Epilepticus, Refractory Status Epilepticus, and Super-refractory Status Epilepticus
Continuum, 2018Status epilepticus, refractory status epilepticus, and super-refractory status epilepticus can be life-threatening conditions. This article presents an overview of the three conditions and discusses their management and outcomes.Status epilepticus was previously defined as lasting for 30 minutes or longer but now is more often defined as lasting 5 ...
Sarah E, Nelson, Panayiotis N, Varelas
openaire +2 more sources
Current Opinion in Critical Care, 2012
Refractory status epilepticus (RSE) has a high morbidity and mortality. There are currently no definitive data to guide both the optimal choice of therapy and treatment goals. This review focuses on RSE diagnosis and outcome and discusses both commonly used and anecdotal therapies for RSE.The challenges in performing randomized controlled trials (RCTs)
Andres, Fernandez, Jan, Claassen
openaire +2 more sources
Refractory status epilepticus (RSE) has a high morbidity and mortality. There are currently no definitive data to guide both the optimal choice of therapy and treatment goals. This review focuses on RSE diagnosis and outcome and discusses both commonly used and anecdotal therapies for RSE.The challenges in performing randomized controlled trials (RCTs)
Andres, Fernandez, Jan, Claassen
openaire +2 more sources
Journal of Palliative Medicine, 2004
A31-YEAR-OLD COMPUTER CONSULTANT was admitted to the hospital for intractable nausea and vomiting. He had presented 18 months earlier with a perforated bowel after a long history of Crohn’s disease. At surgical exploration he was found to have a perforated appendiceal cancer with omental and peritoneal metastases treated with a right hemicolectomy and ...
Mary, Golf +5 more
openaire +2 more sources
A31-YEAR-OLD COMPUTER CONSULTANT was admitted to the hospital for intractable nausea and vomiting. He had presented 18 months earlier with a perforated bowel after a long history of Crohn’s disease. At surgical exploration he was found to have a perforated appendiceal cancer with omental and peritoneal metastases treated with a right hemicolectomy and ...
Mary, Golf +5 more
openaire +2 more sources
Status epilepticus: Refractory and super-refractory
Neurology India, 2017Status epilepticus (SE) is an important neurological emergency. It is defined as seizures lasting for 5 minutes or more or recurrent seizures without recovery of consciousness to baseline between the attacks. Refractory SE (RSE) is defined as SE persisting despite sufficient dose of benzodiazepines and at least one antiepileptic drug (AED ...
Deepanshu, Dubey +2 more
openaire +2 more sources
Neurology, 1998
Mortality and morbidity associated with status epilepticus (SE) are, to a large extent, determined by the etiology underlying SE and the rapidity with which seizures are controlled.1 Most patients with SE will respond to aggressive treatment protocols that include repeated high doses of phenytoin, phenobarbital, and benzodiazepine.
R D, Sheth, B E, Gidal
openaire +2 more sources
Mortality and morbidity associated with status epilepticus (SE) are, to a large extent, determined by the etiology underlying SE and the rapidity with which seizures are controlled.1 Most patients with SE will respond to aggressive treatment protocols that include repeated high doses of phenytoin, phenobarbital, and benzodiazepine.
R D, Sheth, B E, Gidal
openaire +2 more sources
Hypothermia for Refractory Status Epilepticus
Neurocritical Care, 2008Status epilepticus (SE) can be refractory to conventional anticonvulsants, requiring anesthetic doses of medications to suppress seizures. This approach carries significant morbidity, is associated with a high fatality rate, and may not always control SE.
Jesse J, Corry +3 more
openaire +2 more sources
Super-Refractory Status Epilepticus
Current Neurology and Neuroscience Reports, 2015Although the vast majority of patients with status epilepticus (SE) respond fairly well to the first- or second-line anti-epileptics, a minority require anesthetic agents to put the seizures under control. An even smaller number of patients do not even respond to those and constitute the subgroup of super-refractory SE.
Mauricio Ruiz, Cuero +1 more
openaire +2 more sources
Neurology India, 2006
Refractory status epilepticus (RSE) is a common problem in intensive care units and emergency departments. The important risk factor predisposing patients with SE to RSE is delay in receiving treatment. Self-sustaining SE is associated with progressive, time-dependent development of pharmacoresistance.
openaire +2 more sources
Refractory status epilepticus (RSE) is a common problem in intensive care units and emergency departments. The important risk factor predisposing patients with SE to RSE is delay in receiving treatment. Self-sustaining SE is associated with progressive, time-dependent development of pharmacoresistance.
openaire +2 more sources
VNS for refractory status epilepticus
Epilepsy Research, 2015Our goal was to perform a systematic review of the literature on the insertion of vagal nerve stimulators (VNS) for refractory status epilepticus (RSE) and its impact on the control of RSE.All articles from MEDLINE, BIOSIS, EMBASE, Global Health, HealthStar, Scopus, Cochrane Library, the International Clinical Trials Registry Platform, clinicaltrials ...
F.A. Zeiler +4 more
openaire +2 more sources